Garwin Gerstein & Fisher LLP

About The Firm

Established more than 60 years ago by its predecessors, Garwin Gerstein & Fisher LLP ("GGF") is a boutique law firm that has championed the rights of small businesses, consumers and investors since its inception. Residing in Manhattan's Financial District, GGF is renowned nationwide as a leading plaintiffs' firm specializing in complex litigation.

The firm focuses predominantly on antitrust litigation involving price-fixing, market allocation and monopolization in the pharmaceutical, medical device and agricultural industries. In addition to its large antitrust practice, GGF also handles complex litigation dealing with unfair and deceptive trade practices.

The firm routinely serves as lead or co-lead class counsel for plaintiffs, and has an AV-rating by Martindale-Hubbell, indicating the high level of skill and ethical standards of its experienced attorneys.

Through its expertise and diligence, and commitment to prosecuting cases through trial (and if necessary, appeal), GGF has achieved numerous multi-million dollar recoveries on behalf of its clients. The following cases represent just a sampling of some of the most recent prominent litigations in which the firm has had a court-appointed leadership role:

  • In re Remeron Antitrust Litigation: serving as co-lead counsel, GGF achieved a $75 million recovery for clients who suffered antitrust damages allegedly resulting from a corporation's anticompetitive attempts to improperly extend its patent protection and market exclusivity.

  • In re Relafen Antitrust Litigation: serving as co-lead counsel, GGF achieved a $175 million recovery for clients who suffered antitrust damages allegedly resulting from a company's use of fraudulently procured patents in attempting to monopolize the market for its branded pharmaceutical product.

  • In re Tricor Antitrust Litigation: serving as co-lead counsel, GGF achieved a $250 million recovery for clients who suffered antitrust damages allegedly resulting from a company's anticompetitive conduct in seeking to keep generic versions of a pharmaceutical product out of the market.

  • In re Neurontin Antitrust Litigation: serving as lead counsel, GGF achieved a $190 million recovery for clients who suffered antitrust damages allegedly resulting from a company's filing of sham patent litigation and engaging in other anticompetitive conduct in seeking to keep generic versions of a pharmaceutical product out of the market.

GGF consistently provides high quality representation in meeting our clients' litigation expectations and goals. If you wish to inquire further about a potential litigation matter, please see our Contact Us page.